{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:22:19Z","timestamp":1786324939437,"version":"build-2736575974"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.maturitas.2014.07.009","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T11:16:34Z","timestamp":1406027794000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Systemic progesterone therapy\u2014Oral, vaginal, injections and even transdermal?"],"prefix":"10.1016","volume":"79","author":[{"given":"Xiangyan","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred.O.","family":"Mueck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2014.07.009_bib0450","series-title":"The pharmacological basis of therapeutics","first-page":"1411","article-title":"Estrogens and progestins","author":"Williams","year":"1996"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/frne.1998.0167","article-title":"Regulation of the human menstrual cycle","volume":"19","author":"Chabbert Buffet","year":"1998","journal-title":"Front Neuroendocrinol."},{"key":"10.1016\/j.maturitas.2014.07.009_bib0015","first-page":"502","article-title":"Physiological action of progesterone in target tissues","volume":"18","author":"Graham","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1210\/jcem-11-3-267","article-title":"Secretory and decidual changes induced in the endometrium of oophorectomized women by administration of estrogen and progesterone","volume":"11","author":"Bradbury","year":"1951","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0025","first-page":"514","article-title":"Endocrine and paracrine regulation of birth at term and preterm","volume":"21","author":"Challis","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1210\/er.2003-0020","article-title":"Molecular cues to implantation","volume":"25","author":"Dey","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0035","doi-asserted-by":"crossref","first-page":"e009","DOI":"10.1621\/nrs.07009","article-title":"Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression","volume":"7","author":"Scarpin","year":"2009","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0040","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/j.1460-2075.1990.tb08280.x","article-title":"Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B","volume":"9","author":"Kastner","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0045","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1096\/fj.08-113639","article-title":"Nuclear matrix binding is critical for progesterone receptor movement into nuclear foci","volume":"23","author":"Graham","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0050","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1210\/jc.2003-031111","article-title":"Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium","volume":"89","author":"Arnett-Mansfield","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/me.2006-0041","article-title":"Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity","volume":"21","author":"Arnett-Mansfield","year":"2007","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0060","series-title":"Godman & Gilman's the pharmacological basis of therapeutics","first-page":"1541","article-title":"Estrogens and progestins","author":"Loose","year":"2006"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0065","first-page":"355","article-title":"Biodisponibilit\u00e9 de la progest\u00e9rone naturelle administr\u00e9e par voie orale. Mesure des concentrations du st\u00e9ro\u00efde dans le plasma, l\u2019endom\u00eatre et le tissu mammaire","volume":"11","author":"Morville","year":"1982","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0070","unstructured":"Utrogest Fachinformation der Dr. Kade Besins Pharma GmbH. Stand. August 2011."},{"key":"10.1016\/j.maturitas.2014.07.009_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","article-title":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"275","author":"Writing Group for the PEPI trial","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0378-5122(01)00170-0","article-title":"Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause","volume":"40","author":"P\u00e9lissier","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5122(02)00031-2","article-title":"Endometrial safety of hormone replacement therapy: review of literature","volume":"42","author":"Van Gorp","year":"2004","journal-title":"Maturitas"},{"issue":"7 Suppl. 1","key":"10.1016\/j.maturitas.2014.07.009_bib0090","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1210\/jc.2009-2509","article-title":"Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement","volume":"95","author":"Santen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/WHE.12.69","article-title":"The kronos early estrogen prevention study by Charlotte Barker","volume":"9","author":"Manson","year":"2013","journal-title":"Womens Health (Lond Engl)"},{"issue":"Suppl 12B","key":"10.1016\/j.maturitas.2014.07.009_bib0100","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjmed.2005.09.008","article-title":"The menopausal transition","volume":"118","author":"Santoro","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0378-5122(90)90086-L","article-title":"Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders","volume":"12","author":"Saarikoski","year":"1990","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0110","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0015-0282(16)54714-1","article-title":"Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea","volume":"56","author":"Shangold","year":"1991","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0115","first-page":"188","article-title":"Progesterone administration in patients with absent ovaries","volume":"34","author":"Devroey","year":"1989","journal-title":"Int J Fertil"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0015-0282(16)56935-0","article-title":"Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study","volume":"63","author":"Miles","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0125","first-page":"403","article-title":"Direct transport of progesterone from vagina to uterus","volume":"95","author":"Cicinelli","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0130","first-page":"CD009154","article-title":"Luteal phase support for assisted reproduction cycles","volume":"10","author":"van der Linden","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0135","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S0015-0282(01)02872-2","article-title":"A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization\u2014embryo transfer cycles","volume":"79","author":"Propst","year":"2001","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0140","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.fertnstert.2014.01.018","article-title":"Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone","volume":"101","author":"Casper","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/09513590.2012.736560","article-title":"Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route","volume":"29","author":"Sator","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0150","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.fertnstert.2013.09.010","article-title":"Onbehalf of 13 European Centers Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study","volume":"101","author":"Lockwood","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0155","first-page":"7","article-title":"Only micronized progesterone is needed to substitute the luteal phase in stimulated cycles","volume":"20","author":"Devroey","year":"1992","journal-title":"Contracept Fertil Sex"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/oxfordjournals.humrep.a137611","article-title":"A prospective randomized comparison on intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement","volume":"7","author":"Smitz","year":"1992","journal-title":"Hum Reprod"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1055\/s-2006-924189","article-title":"Die vaginale Anwendung von nat\u00fcrlichem Progesteron als Lutealphasenunterst\u00fctzung nach IVF und Embryotransfer","volume":"66","author":"Griesinger","year":"2006","journal-title":"Geburts Frauenheilk"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0170","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.rbmo.2013.10.022","article-title":"Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey","volume":"28","author":"Vaisbuch","year":"2014","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0175","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMe030081","article-title":"Progesterone and preterm delivery\u2014Deja vu all over again","volume":"348","author":"Greene","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0180","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"National Institute of Child Health and Human Development Maternal\u2013Fetal Medicine Units Network Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0185","first-page":"60","article-title":"Progesterone supplementation and the prevention of preterm birth","volume":"4","author":"Norwitz","year":"2011","journal-title":"Rev Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0190","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa067815","article-title":"for the Fetal Medicine Foundation Second Trimester Screening Group: progesterone and the risk of preterm birth among women with a short cervix","volume":"357","author":"Fonseca","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0195","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/uog.9017","article-title":"Pregnant trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, plazebo-controlled trial","volume":"38","author":"Hassan","year":"2011","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"124","key":"10.1016\/j.maturitas.2014.07.009_bib0200","first-page":"e1","article-title":"Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data","volume":"206","author":"Romero","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0205","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","author":"Society for Maternal\u2013Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0210","first-page":"227","article-title":"Drohende Fr\u00fchgeburt: Pr\u00e4vention, Diagnostik und Therapie","volume":"110","author":"Schleu\u00dfner","year":"2013","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0015-0282(16)57482-2","article-title":"Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo","volume":"63","author":"Chang","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0220","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0015-0282(98)00042-9","article-title":"Estradiol and progesterone regulate the proliferation of human breast epithelial cells","volume":"69","author":"Foidart","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0225","series-title":"Percutaneous absorption of steroids","first-page":"218","article-title":"Treatment of benign breast diseases by progesterone applied topically","author":"Sitruk-Ware","year":"1980"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0230","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00042192-200512020-00019","article-title":"Percutaneous administration of progesterone: blood levels and endometrial protection","volume":"12","author":"Stanczyk","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5694\/j.1326-5377.2005.tb06676.x","article-title":"Transdermal progesterone creams for postmenopausal women: more hype than hope?","volume":"182","author":"Wren","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0240","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0002-9378(99)70046-3","article-title":"Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen","volume":"180","author":"Burry","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0245","doi-asserted-by":"crossref","first-page":"626","DOI":"10.18433\/J3RW2H","article-title":"Transdermal delivery of bioidentical progesterone using dutasteride (A 5\u03b1-reductase inhibitor): a pilot study","volume":"13","author":"Zargar-Shoshtari","year":"2010","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/13697130008500109","article-title":"Effect of sequential transdermal progesterone cream on endometrium bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women","volume":"3","author":"Wren","year":"2000","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0255","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(05)79323-5","article-title":"Systemic absorption of progesterone from progest cream in postmenopausal women","volume":"351","author":"Cooper Spencer","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0260","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1471-0528.2000.tb13331.x","article-title":"A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women","volume":"107","author":"Carey","year":"2000","journal-title":"Br J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5122(01)00250-X","article-title":"Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women","volume":"41","author":"Lewis","year":"2002","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/09513590500128583","article-title":"A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen","volume":"21","author":"Vashisht","year":"2005","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0275","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/jnci\/djh336","article-title":"Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women","volume":"96","author":"Missmer","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1258\/mi.2009.009014","article-title":"A double-blind plazebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women","volume":"15","author":"Benster","year":"2009","journal-title":"Menopause Int"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0285","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/0091270005276621","article-title":"Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration-approved oral progesterone product","volume":"45","author":"Hermann","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0290","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/01443610701582727","article-title":"Transdermal natural progesterone cream for postmenopausal women: inconsistent data and complex pharmacokinetics","volume":"27","author":"Elshafie","year":"2007","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0295","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2265.2000.01130.x","article-title":"Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women","volume":"53","author":"\u00d3Leary","year":"2000","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0300","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/GME.0b013e31828d39a2","article-title":"Percutaneous progesterone delivery through cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood","volume":"20","author":"Du","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2013.10.006","article-title":"Percutaneous absorption of progesterone","volume":"77","author":"Zava","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0310","series-title":"EMEA\/CHMP\/021\/97 Rev. 1","article-title":"Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women","author":"Committee for Medicinal Products for Human use (CHMP)","year":"2005"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0315","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1471-0528.2005.00689.x","article-title":"Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime","volume":"112","author":"Vashisht","year":"2005","journal-title":"BJOG"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0320","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2007.01.001","article-title":"One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women","volume":"57","author":"Samsioe","year":"2007","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0325","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/01.gme.0000177318.24005.b1","article-title":"Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial","volume":"12","author":"Archer","year":"2005","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0330","first-page":"36","article-title":"Transdermal progesterone cream as an alternative progestin in hormone therapy","volume":"11","author":"Leonetti","year":"2005","journal-title":"Altern Ther Health Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0015-0282(02)04542-9","article-title":"Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium","volume":"79","author":"Leonetti","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0340","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/13697130008500109","article-title":"Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women","volume":"3","author":"Wren","year":"2000","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0345","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/gme.0b013e31824b970a","article-title":"The 2012 hormone therapy position statement of: The North American Menopause Society","volume":"19","author":"North American Menopause Society","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0350","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.1980.03310130021021","article-title":"Oral medroxyprogesterone in the treatment of postmenopausal symptoms","volume":"244","author":"Schiff","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0355","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9378(81)90475-0","article-title":"Objective evidence that plazebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes","volume":"139","author":"Albrecht","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0360","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0378-5122(81)90008-6","article-title":"Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women","volume":"3","author":"Erlik","year":"1981","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0365","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0370","first-page":"498","article-title":"The effects of progestins on vasomotor flushes","volume":"27","author":"Schiff","year":"1982","journal-title":"J Reprod Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0375","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/gme.0b013e318247f07a","article-title":"Oral micronized progesterone for vasomotor symptoms\u2014a plazebo-controlled randomized trial in healthy postmenopausal women","volume":"19","author":"Hitchcock","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0380","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.2005.04.7324","article-title":"Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7","volume":"24","author":"Loprinzi","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0385","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.2006.10.6179","article-title":"Phase III randomized plazebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626","volume":"26","author":"Goodwin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0390","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2011.37.5865","article-title":"Nonestrogenic management of hot flashes","volume":"29","author":"Loprinzi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0395","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1345\/aph.1R362","article-title":"Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective","volume":"47","author":"Whelan","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0400","first-page":"225","article-title":"Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss","volume":"94","author":"Leonetti","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0405","first-page":"13","article-title":"Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women","volume":"10","author":"Wren","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0410","series-title":"Guidance for industry: estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms\u2014recommendations for clinical evaluation","author":"US Department of Health and Human Services. FDA","year":"2003"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0415","first-page":"295","article-title":"Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women","volume":"12","author":"Stephenson","year":"2008","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0420","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1258\/mi.2009.009017","article-title":"Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density","volume":"15","author":"Benster","year":"2009","journal-title":"Menopause Int"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0425","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/13697137.2013.795683","article-title":"International Menopause Society Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health","volume":"16","author":"de Villiers","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0435","doi-asserted-by":"crossref","first-page":"626","DOI":"10.18433\/J3RW2H","article-title":"Transdermal delivery of bioidentical progesterone using dutasteride (a 5\u03b1-reductase inhibitor): a pilot study","volume":"13","author":"Zargar-Shoshtari","year":"2010","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0440","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/IJGM.S16139","article-title":"Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study","volume":"4","author":"Formby","year":"2011","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.maturitas.2014.07.009_bib0445","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF03192300","article-title":"Pharmacokinetics of progesterone in postmenopausal women: 2 pharmacokinetics following percutaneous administration","volume":"23","author":"Mircioiu","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214002382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512214002382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:01:03Z","timestamp":1759914063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512214002382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0378512214002382"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.07.009","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic progesterone therapy\u2014Oral, vaginal, injections and even transdermal?","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2014.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}